Lee Y, Kim M, Kim E, Park C, Cho J, Ko B
Lung. 2025; 203(1):41.
PMID: 40067456
DOI: 10.1007/s00408-025-00794-7.
Matsumoto K, Akieda Y, Haraoka Y, Hirono N, Sasaki H, Ishitani T
Nat Commun. 2024; 15(1):10662.
PMID: 39690179
PMC: 11652645.
DOI: 10.1038/s41467-024-55108-x.
Khin M, Davis L, Lantvit D, Orjala J, Burdette J
Mol Pharmacol. 2024; 106(3):145-154.
PMID: 39079718
PMC: 11331498.
DOI: 10.1124/molpharm.124.000921.
Ribeiro C, Ferreirinha P, Landry J, Macedo F, Sousa L, Pinto R
Cell Death Dis. 2024; 15(5):352.
PMID: 38773063
PMC: 11109193.
DOI: 10.1038/s41419-024-06728-0.
Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S
Cell Death Dis. 2023; 14(9):642.
PMID: 37773170
PMC: 10541907.
DOI: 10.1038/s41419-023-06168-2.
Network pharmacology-based analysis of potential mechanisms of myocardial ischemia-reperfusion injury by total salvianolic acid injection.
Li N, Gu X, Liu F, Zhang Y, Sun Y, Gao S
Front Pharmacol. 2023; 14:1202718.
PMID: 37680709
PMC: 10482107.
DOI: 10.3389/fphar.2023.1202718.
Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis.
Liang R, Lin M, Menon V, Qiu J, Menon A, Breda L
Blood Adv. 2023; 7(22):6873-6885.
PMID: 37672319
PMC: 10685172.
DOI: 10.1182/bloodadvances.2022007655.
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer.
Sarosiek K, Wood K
Trends Cancer. 2023; 9(2):96-110.
PMID: 37284233
PMC: 10241480.
DOI: 10.1016/j.trecan.2022.10.004.
Circulating cardiac MicroRNAs safeguard against dilated cardiomyopathy.
Cheng X, Jian D, Xing J, Liu C, Liu Y, Cui C
Clin Transl Med. 2023; 13(5):e1258.
PMID: 37138538
PMC: 10157268.
DOI: 10.1002/ctm2.1258.
Non-coding RNAs and Exosomal Non-coding RNAs in Traumatic Brain Injury: the Small Player with Big Actions.
Mohamadzadeh O, Hajinouri M, Moammer F, Tamehri Zadeh S, Omid Shafiei G, Jafari A
Mol Neurobiol. 2023; 60(7):4064-4083.
PMID: 37020123
DOI: 10.1007/s12035-023-03321-y.
The Expression of FOXO3a as a Forensic Diagnostic Tool in Cases of Traumatic Brain Injury: An Immunohistochemical Study.
Maiese A, Spina F, Visi G, Del Duca F, De Matteis A, La Russa R
Int J Mol Sci. 2023; 24(3).
PMID: 36768906
PMC: 9916452.
DOI: 10.3390/ijms24032584.
The CRL4 E3 ligase ubiquitinates CtBP1/2 to induce apoptotic signalling and promote intervertebral disc degeneration.
Tseng C, Han Y, Lv Z, Song Q, Wang K, Shen H
J Mol Med (Berl). 2023; 101(1-2):171-181.
PMID: 36688959
DOI: 10.1007/s00109-022-02277-1.
Serum and glucocorticoid-regulated kinase 1: Structure, biological functions, and its inhibitors.
Jang H, Park Y, Jang J
Front Pharmacol. 2022; 13:1036844.
PMID: 36457711
PMC: 9706101.
DOI: 10.3389/fphar.2022.1036844.
BCL-2 protein family: attractive targets for cancer therapy.
Kaloni D, Diepstraten S, Strasser A, Kelly G
Apoptosis. 2022; 28(1-2):20-38.
PMID: 36342579
PMC: 9950219.
DOI: 10.1007/s10495-022-01780-7.
Identification of as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS).
Faltus C, Lahnsteiner A, Barrdahl M, Assenov Y, Husing A, Bogatyrova O
Int J Mol Sci. 2022; 23(18).
PMID: 36142605
PMC: 9505874.
DOI: 10.3390/ijms231810699.
The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma.
Sellin M, Berg S, Hagen P, Zhang J
Transl Oncol. 2022; 22:101448.
PMID: 35660848
PMC: 9166471.
DOI: 10.1016/j.tranon.2022.101448.
The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.
Timilsina S, Rajamanickam S, Rao A, Subbarayalu P, Nirzhor S, Abdelfattah N
Cancer Lett. 2022; 540:215717.
PMID: 35568265
PMC: 10313451.
DOI: 10.1016/j.canlet.2022.215717.
B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.
Teymouri Nobari S, Nouri Nojadeh J, Talebi M
J Transl Med. 2022; 20(1):82.
PMID: 35144648
PMC: 8832753.
DOI: 10.1186/s12967-022-03285-y.
Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling.
Yang F, Zhang L, Zheng Y, Dong H
Bioengineered. 2022; 13(1):1377-1387.
PMID: 34974801
PMC: 8805856.
DOI: 10.1080/21655979.2021.2017611.
Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment.
Cowell J, Hu T
Cancer Drug Resist. 2021; 4:607-619.
PMID: 34734169
PMC: 8562765.
DOI: 10.20517/cdr.2021.30.